ThyCa News

Lenvatinib Shows Positive Results in Clinical Trial


Lenvatinib shows promising results as a treatment option for people with differentiated radioiodine-resistant thyroid cancer, according to a Phase III clinical trial reported at the meeting of the American Society of Clinical Oncology (ASCO). 

Lead study author is Martin Schlumberger, M.D., Oncology Professor at University Paris Sud, France and ThyCa Medical Advisor. 

A summary of the presentation at ASCO is here.

News Archive